Uncharacterized Protein, Uncharacterized
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Cuervo et al. | no | yes: 0 | 
| Hassani et al. | no | yes: 0 | 
| Forrest at al. (metacyclic) | no | yes: 0 | 
| Forrest at al. (procyclic) | no | yes: 0 | 
| Silverman et al. | no | yes: 0 | 
| Pissara et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Pires et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Silverman et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Jamdhade et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 1, no: 11 | 
| NetGPI | no | yes: 0, no: 12 | 
Related structures:
AlphaFold database: A4IAC2
| Leishmania | From | To | Domain/Motif | Score | 
|---|---|---|---|---|
| CLV_NRD_NRD_1 | 235 | 237 | PF00675 | 0.562 | 
| CLV_NRD_NRD_1 | 262 | 264 | PF00675 | 0.557 | 
| CLV_NRD_NRD_1 | 90 | 92 | PF00675 | 0.424 | 
| CLV_PCSK_KEX2_1 | 234 | 236 | PF00082 | 0.552 | 
| CLV_PCSK_KEX2_1 | 262 | 264 | PF00082 | 0.557 | 
| CLV_PCSK_SKI1_1 | 16 | 20 | PF00082 | 0.447 | 
| CLV_PCSK_SKI1_1 | 196 | 200 | PF00082 | 0.502 | 
| DEG_COP1_1 | 250 | 259 | PF00400 | 0.635 | 
| DOC_CKS1_1 | 136 | 141 | PF01111 | 0.396 | 
| DOC_MAPK_gen_1 | 132 | 142 | PF00069 | 0.298 | 
| DOC_MAPK_gen_1 | 179 | 188 | PF00069 | 0.262 | 
| DOC_MAPK_MEF2A_6 | 148 | 156 | PF00069 | 0.396 | 
| DOC_MAPK_MEF2A_6 | 179 | 188 | PF00069 | 0.262 | 
| DOC_MAPK_MEF2A_6 | 247 | 256 | PF00069 | 0.502 | 
| DOC_USP7_MATH_1 | 212 | 216 | PF00917 | 0.488 | 
| DOC_USP7_MATH_1 | 274 | 278 | PF00917 | 0.507 | 
| DOC_WW_Pin1_4 | 135 | 140 | PF00397 | 0.249 | 
| DOC_WW_Pin1_4 | 168 | 173 | PF00397 | 0.328 | 
| DOC_WW_Pin1_4 | 282 | 287 | PF00397 | 0.633 | 
| DOC_WW_Pin1_4 | 45 | 50 | PF00397 | 0.335 | 
| DOC_WW_Pin1_4 | 68 | 73 | PF00397 | 0.328 | 
| LIG_14-3-3_CanoR_1 | 234 | 239 | PF00244 | 0.564 | 
| LIG_Actin_WH2_2 | 180 | 198 | PF00022 | 0.375 | 
| LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.483 | 
| LIG_FHA_1 | 149 | 155 | PF00498 | 0.425 | 
| LIG_FHA_1 | 305 | 311 | PF00498 | 0.669 | 
| LIG_FHA_2 | 311 | 317 | PF00498 | 0.574 | 
| LIG_FHA_2 | 65 | 71 | PF00498 | 0.412 | 
| LIG_LIR_Apic_2 | 280 | 286 | PF02991 | 0.468 | 
| LIG_LIR_Apic_2 | 334 | 339 | PF02991 | 0.537 | 
| LIG_LIR_Gen_1 | 150 | 160 | PF02991 | 0.353 | 
| LIG_LIR_Gen_1 | 2 | 8 | PF02991 | 0.303 | 
| LIG_LIR_Gen_1 | 71 | 82 | PF02991 | 0.396 | 
| LIG_LIR_Nem_3 | 150 | 156 | PF02991 | 0.318 | 
| LIG_LIR_Nem_3 | 178 | 184 | PF02991 | 0.418 | 
| LIG_LIR_Nem_3 | 2 | 6 | PF02991 | 0.287 | 
| LIG_LIR_Nem_3 | 33 | 38 | PF02991 | 0.310 | 
| LIG_LIR_Nem_3 | 71 | 77 | PF02991 | 0.396 | 
| LIG_NRBOX | 118 | 124 | PF00104 | 0.344 | 
| LIG_SH2_CRK | 283 | 287 | PF00017 | 0.564 | 
| LIG_SH2_CRK | 336 | 340 | PF00017 | 0.631 | 
| LIG_SH2_NCK_1 | 283 | 287 | PF00017 | 0.504 | 
| LIG_SH2_NCK_1 | 336 | 340 | PF00017 | 0.504 | 
| LIG_SH2_PTP2 | 35 | 38 | PF00017 | 0.319 | 
| LIG_SH2_PTP2 | 74 | 77 | PF00017 | 0.396 | 
| LIG_SH2_SRC | 336 | 339 | PF00017 | 0.552 | 
| LIG_SH2_SRC | 87 | 90 | PF00017 | 0.288 | 
| LIG_SH2_STAT5 | 141 | 144 | PF00017 | 0.314 | 
| LIG_SH2_STAT5 | 153 | 156 | PF00017 | 0.323 | 
| LIG_SH2_STAT5 | 35 | 38 | PF00017 | 0.305 | 
| LIG_SH2_STAT5 | 39 | 42 | PF00017 | 0.297 | 
| LIG_SH2_STAT5 | 74 | 77 | PF00017 | 0.257 | 
| LIG_SH2_STAT5 | 87 | 90 | PF00017 | 0.230 | 
| LIG_SH3_3 | 253 | 259 | PF00018 | 0.542 | 
| LIG_SH3_3 | 284 | 290 | PF00018 | 0.482 | 
| LIG_SH3_3 | 95 | 101 | PF00018 | 0.288 | 
| LIG_TRAF2_1 | 134 | 137 | PF00917 | 0.385 | 
| LIG_TRAF2_1 | 277 | 280 | PF00917 | 0.484 | 
| LIG_WRC_WIRS_1 | 118 | 123 | PF05994 | 0.198 | 
| MOD_CK2_1 | 174 | 180 | PF00069 | 0.468 | 
| MOD_CK2_1 | 274 | 280 | PF00069 | 0.499 | 
| MOD_CK2_1 | 310 | 316 | PF00069 | 0.690 | 
| MOD_CK2_1 | 64 | 70 | PF00069 | 0.344 | 
| MOD_GlcNHglycan | 123 | 126 | PF01048 | 0.385 | 
| MOD_GlcNHglycan | 32 | 35 | PF01048 | 0.295 | 
| MOD_GSK3_1 | 117 | 124 | PF00069 | 0.417 | 
| MOD_GSK3_1 | 197 | 204 | PF00069 | 0.551 | 
| MOD_GSK3_1 | 64 | 71 | PF00069 | 0.367 | 
| MOD_N-GLC_1 | 30 | 35 | PF02516 | 0.372 | 
| MOD_NEK2_1 | 121 | 126 | PF00069 | 0.410 | 
| MOD_NEK2_1 | 73 | 78 | PF00069 | 0.389 | 
| MOD_PK_1 | 324 | 330 | PF00069 | 0.540 | 
| MOD_PKA_1 | 234 | 240 | PF00069 | 0.500 | 
| MOD_PKA_2 | 102 | 108 | PF00069 | 0.458 | 
| MOD_PKA_2 | 234 | 240 | PF00069 | 0.585 | 
| MOD_PKA_2 | 299 | 305 | PF00069 | 0.601 | 
| MOD_PKA_2 | 64 | 70 | PF00069 | 0.255 | 
| MOD_Plk_4 | 117 | 123 | PF00069 | 0.369 | 
| MOD_Plk_4 | 148 | 154 | PF00069 | 0.422 | 
| MOD_Plk_4 | 305 | 311 | PF00069 | 0.599 | 
| MOD_ProDKin_1 | 135 | 141 | PF00069 | 0.249 | 
| MOD_ProDKin_1 | 168 | 174 | PF00069 | 0.328 | 
| MOD_ProDKin_1 | 282 | 288 | PF00069 | 0.637 | 
| MOD_ProDKin_1 | 45 | 51 | PF00069 | 0.335 | 
| MOD_ProDKin_1 | 68 | 74 | PF00069 | 0.328 | 
| MOD_SUMO_rev_2 | 167 | 172 | PF00179 | 0.264 | 
| MOD_SUMO_rev_2 | 177 | 184 | PF00179 | 0.266 | 
| MOD_SUMO_rev_2 | 250 | 257 | PF00179 | 0.580 | 
| TRG_ENDOCYTIC_2 | 153 | 156 | PF00928 | 0.290 | 
| TRG_ENDOCYTIC_2 | 181 | 184 | PF00928 | 0.304 | 
| TRG_ENDOCYTIC_2 | 35 | 38 | PF00928 | 0.310 | 
| TRG_ENDOCYTIC_2 | 74 | 77 | PF00928 | 0.396 | 
| TRG_ER_diArg_1 | 206 | 209 | PF00400 | 0.535 | 
| TRG_ER_diArg_1 | 233 | 236 | PF00400 | 0.522 | 
| TRG_ER_diArg_1 | 261 | 263 | PF00400 | 0.553 | 
| TRG_Pf-PMV_PEXEL_1 | 276 | 280 | PF00026 | 0.518 | 
| Protein | Taxonomy | Sequence identity | Coverage | 
|---|---|---|---|
| A0A0N1PB55 | Leptomonas seymouri | 67% | 100% | 
| A0A0S4IZ37 | Bodo saltans | 25% | 93% | 
| A0A1X0PAB8 | Trypanosomatidae | 47% | 100% | 
| A0A3Q8IFT3 | Leishmania donovani | 100% | 100% | 
| A0A3R7RA24 | Trypanosoma rangeli | 43% | 100% | 
| A4HB74 | Leishmania braziliensis | 86% | 100% | 
| C9ZLX0 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 44% | 100% | 
| E9B1A1 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 26% | 83% | 
| E9B5E5 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 92% | 100% | 
| Q4Q2I8 | Leishmania major | 93% | 100% | 
| V5B6C0 | Trypanosoma cruzi | 48% | 93% |